Effect of Helicobacter pylori eradication therapy on risk of hospitalization for a major ulcer event

Pharmacotherapy

Volumn 31, Issue 3, 2011, Pages 239-247

  Hsiao, Fei Yuan ^a,b   Tsai, Yi Wen ^c,d   Wen, Yu Wen ^e   Kuo, Ken N ^c   Tsai, Chia Rung ^c   Huang, Weng Foung ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Gastrointestinal ulcer; H 2 blocker; Helicobacter pylori eradication therapy; Hospitalization; PPI; Proton pump inhibitor

Indexed keywords

AMOXICILLIN; ANTIULCER AGENT; CIMETIDINE; CLARITHROMYCIN; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; ROXATIDINE; STOMACH SECRETION INHIBITOR; TETRACYCLINE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; EARLY INTERVENTION; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; RISK FACTOR; STOMACH PROTECTION; THERAPY EFFECT;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; COMORBIDITY; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HOSPITALIZATION; HUMANS; MALE; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PEPTIC ULCER PERFORATION; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK; TAIWAN; TREATMENT OUTCOME;

EID: 79952365976     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.3.239     Document Type: Article

References (27)

1. Sung J. Current management of peptic ulcer bleeding. Nat Clin Pract Gastroenterol Hepatol 2006;3:24-32. (Pubitemid 43102074)
2. Theocharis GJ, Thomopoulos KC, Sakellaropoulos G, Katsakoulis E, Nikolopoulou V. Changing trends in the epidemiology and clinical outcome of acute upper gastrointestinal bleeding in a defined geographical area in Greece. J Clin Gastroenterol 2008;42:128-33.
3. Moayyedi P. The health economics of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol 2007;21:347-61.
4. Naja F, Kreiger N, Sullivan T. Helicobacter pylori infection in Ontario: prevalence and risk factors. Can J Gastroenterol 2007;21:501-6.
5. Cucino C, Sonnenberg A. The long-term time trends of ulcerative colitis and peptic ulcer are interrelated. Am J Gastroenterol 2002;97:2657-62.
6. Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology 2007;132:2320-7. (Pubitemid 46890869)
7. Sonnenberg A. Time trends of ulcer mortality in non-European countries. Am J Gastroenterol 2007;102:1101-7. (Pubitemid 46698237)
8. Kang JY, Elders A, Majeed A, Maxwell JD, Bardhan KD. Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982-2002. Aliment Pharmacol Ther 2006;24:65-79.
9. Paimela H, Paimela L, Myllykangas-Luosujärvi R, Kivilaakso E. Current features of peptic ulcer disease in Finland: incidence of surgery, hospital admissions and mortality for the disease during the past twenty-five years. Scand J Gastroenterol 2002;37:399-403. (Pubitemid 34274322)
10. Bardhan KD, Williamson M, Royston C, Lyon C. Admission rates for peptic ulcer in the trent region, UK, 1972-2000: changing pattern, a changing disease? Dig Liver Dis 2004;36:577-88.
11. Xia B, Xia HH, Ma CW, et al. Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong. Aliment Pharmacol Ther 2005;22:243-9.
12. Bardhan KD, Royston C. Time, change and peptic ulcer disease in Rotherham, UK. Dig Liver Dis 2008;40:540-6.
13. Sonnenberg A, Cucino C, Bauerfeind P. Commentary: the unresolved mystery of birth-cohort phenomena in gastroenterology. Int J Epidemiol 2002;31:23-6. (Pubitemid 34284894)
14. Harvey RF, Spence RW, Lane JA, et al. Relationship between the birth cohort pattern of Helicobacter pylori infection and the epidemiology of duodenal ulcer. QJM 2002;95:519-25.
15. Sonnenberg A. Causes underlying the birth-cohort phenomenon of peptic ulcer: analysis of mortality data 1911-2000, England and Wales. Int J Epidemiol 2006;35:1090-7.
16. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833-55.
17. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006;(2):CD003840.
18. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz JE. H. pylori eradication therapy vs. antisecretory noneradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev 2004;(2):CD004062.
19. World Health Organization Collaborating Centre for Drug Statistics Methodology. The ATC and DDD system. Available from:http://www.whocc.no/atcddd/. Accessed March 29, 2009.
20. Kepekci Y, Kadayifci A. Does the eradication of Helicobacter pylori cure duodenal ulcer disease in communities with a high prevalence rate? Comparison with long-term acid suppression. Int J Clin Pract 1999;53:505-8.
21. Monés J, Rodrigo L, Sancho F, et al, for the Club Español para el Estudio del Helicobacter Pylori. Helicobacter pylori eradication versus one-year maintenance therapy: effect on relapse and gastritis outcome. Rev Esp Enferm Dig 2001;93:372-89.
22. Sobhani I, Chastang C, De Korwin JD, et al. Antibiotic versus maintenance therapy in the prevention of duodenal ulcer recurrence: results of a multicentric double-blind randomized trial. Gastroenterol Clin Biol 1995;19:252-8.
23. Wong BC, Lam SK, Lai KC, et al. Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. Aliment Pharmacol Ther 1999;13:303-9.
24. Sone Y, Kumada T, Toyoda H, Yokoyama M, Kato M, Asaka M. Eradicating Helicobacter pylori in peptic ulcer disease reduces medical costs in the community. Helicobacter 2008;13:346-51.
25. Chan FK. Proton-pump inhibitors as a protective treatment for high-risk patients receiving treatment with NSAIDs. Nat Clin Pract Rheumatol 2007;3:694-5. (Pubitemid 350187013)
26. O'connor A, Taneike I, Nami A, et al. Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland. Eur J Gastroenterol Hepatol 2010;22:1123-7.
27. Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 2009;24:1230-5.